Drugs / QLETLI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05180526 | Dec 2021 → Dec 2024 | uveitis | Bio-Thera Solutions | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLETLI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05180526 ↗ |
| Known as | Adalimumab Injection | “A Multicenter, Prospective, Post-marketing Evaluation of QLETLI (Adalimumab Injection) Treatment Clinical Study on Efficacy and Safety of Non-infectious Uveitis (UV)” NCT05180526 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT05180526 ↗ |